

MDxHealth Successfully Raises € 8.2 Million In Equity Issue

DURHAM, NC, and LIEGE, BELGIUM – April 5, 2011 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has successfully raised approximately € 8.2 million in gross proceeds through a private placement of new shares with investors in various jurisdictions. Pursuant to the private placement, MDxHealth will issue 5,436,713 new ordinary shares for an offer price of € 1.50 per share.

“We are delighted to have raised this additional funding from a broad range of international investors who share our belief in the commercial potential of our world leading DNA methylation platform,” said Jan Groen, chief executive officer of MDxHealth. “In combination with our existing cash position, these funds allow us to accelerate the execution of our new business strategy and establish a U.S. presence in the short term.”

The net proceeds of the private placement will increase MDxHealth’s financial flexibility. They will be used to accelerate product development in line with the new business strategy and to set up a CLIA laboratory and hire a sales and marketing team in the US.

The payment and delivery of the new shares is expected to take place on April 8, 2011, at which date the new shares are also expected to be admitted to listing, subject to the approval and publication of a listing prospectus. The new shares will be fungible with the existing shares on NYSE Euronext. Immediately after the closing of the private placement, MDxHealth’s issued and outstanding share capital will increase from 13,185,614 to 18,622,327 ordinary shares.

Kempen & Co and Nomura Code Securities have acted as joint lead managers and joint bookrunners and ING Belgium has acted as co-lead manager in the private placement.

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company’s tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University and Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Pfizer, and other industry leaders. More information can be found on the Company website: www.mdxhealth.com or on twitter at the following address : www.twitter.com/mdxhealth.

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4 364 20 70

Hans Herklots
Capricorn One
+41 79 598 7149

Important information about forward-looking statements

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

Important notice

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of MDxHealth, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. This press release is not an offer of securities for sale into the United States, Canada, Australia or Japan.

The new shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration. The Company does not intend to register any portion of the placing in the United States or to conduct a public offering of securities in the United States.